Projects

SCAI as a project partner?

We are always open for new collaborations – if you are interested, please send an e-mail to:

marketing@scai.fraunhofer.de

Reset
  • REMEDi4ALL – Drug repurposing

    EU-project / Project start  / September 01, 2022

    REMEDi4ALL aims to make a significant leap forward in drug repurposing. This promising approach to drug development, consisting of identifying, testing, and validating new therapeutic indications for existing medications, is a developing field but faces numerous barriers and systemic inefficiencies. Still, its potential to significantly bring down times and costs of drug development - it focuses on already approved, discontinued, shelved or investigational therapeutics - makes this novel strategy attractive for rare and neglected conditions, cancer, emerging public health threats such as COVID-19 or new drug combinations. It also translates into more sustainable health systems.

    more info
  • Biomarkers for depression

    Project start / May 01, 2022

    We aim to validate and commercialise biomarkers and the resulting products for affective disorders to address the many unmet needs along the entire disease trajectory.

    more info
  • © AIOLOS 2022

    The goal of the AIOLOS project (Artificial Intelligence Tools for Outbreak Detection and Response) is to develop a digital platform to allow for early detection of new respiratory pathogens epidemics, monitor their spread, and inform decision-makers on appropriate countermeasures. AIOLOS will provide insights for private and public decision-making in a web-based dashboard, which leverages real-time data from multiple data sources, advanced artificial intelligence (AI), and predictive modeling.

    more info
  • The European project DIGIPD, funded with around 1.6 million euros and coordinated by the Fraunhofer Institute for Algorithms and Scientific Computing SCAI, is investigating the extent to which digital techniques (sensors, speech recognition, recognition of facial expressions) can be used to make a more precise and individualized diagnosis and prognosis of Parkinson's disease. The project is funded by the European network for personalized medicine, ERA PerMed, in the "Joint Transnational Call 2020". The German share of DIGIPD is funded by the Federal Ministry of Education and Research (BMBF).

    more info
  • ZET-O-MAP

    Project start / March 01, 2021

    The zet-o-map project aims to develop better tools for the identification of teratogenic compounds. One of the most promising assays is the zebrafish embryo teratogenicity assay (ZETA). In human risk assessment the evaluation of developmental toxicity or teratogenicity requires the testing of rodents (preferably rats) and non-rodents (preferably rabbits) as described in the OECD 414 guideline. Currently human safety assessment is undergoing a paradigm shift moving towards mechanistic risk assessment and there is a high demand to replace, reduce or refine animal tests where possible for ethical and economic reasons. zet-o-map is funded by the Long Range Research Initiative (LRI) of the European Chemical Industry Council (CEFIC).

    more info
  • Biomedical knowledge graphs

    Project start / January 01, 2021

    Biomedical knowledge graphs play a central role in big data integration. Bringing unstructured text into a structured, comparable format is one of the key assets. As cause and effect models, knowledge graphs can potentially facilitate clinical decision making or help to drive research towards precision medicine. Data and Knowledge Management, sometimes also called Information Management, is a core topic of Data Science. It is also a interdisciplinary field touching economics (how efficient and expensive is the solution?), psychology (do people use this solution in a way that was intended?) and of course computer science. Our aim is to build sustainable data infrastructure for biomedical data, personalized medicine, drug repurposing, reproducible AI and knowledge discovery.

    more info
  • COPERIMOplus – COronavirus PErsonalized RIsk MOdels

    Project start / October 01, 2020

    The Fraunhofer institutes cooperating in COPERIMOplus want to use rational, data-driven modeling to enable individual risk assessments in order to improve the prognosis of disease progression and to optimize personalized therapies and their evaluation based on objective, standardized criteria. Thus, the project contributes to making it possible to live with the pandemic and return to economic and social normality. The project is funded in the Fraunhofer Anti-Corona program.

    more info
  • The overall goal of NFDI4Health is to best support the clinical and epidemiological research community in sharing their data with the user community in accordance with privacy regulations and ethical principles, and to create new opportunities for data analysis within the Nationalen Forschungsdateninfrastruktur (NFDI) in the interest of improving population health. NFDI4Health is funded by the Deutschen Forschungsgemeinschaft (DFG) under the Bund-Länder Agreement on the Establishment and Funding of the NFDI of November 26, 2018.

    more info
  • In the RADAR-AD project, the project partners will develop methods with which the functional loss in the brain of Alzheimer patients can be measured at an early stage - not only in hospitals but also on an outpatient basis. So-called remote measurement tools (RMT) will enable remote assessments and thus improve patient care. The project is funded by the Innovative Medicine Initiative (IMI), a public-private partnership between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

    more info